Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ATPsensor

Financiado

Cerrado

Purine sensors as novel point-of-care devices for seizures and epilepsy

Epilepsy is the most common chronic brain disease, affecting ~70 million people worldwide. Accurately diagnosing epilepsy remains a major clinical challenge due to the lack of non-invasive molecular diagnostic tools. Purinergic si... ver más

22/09/2026

ROYAL COLLEGE OF S...

Presupuesto desconocido

Líder del proyecto

ROYAL COLLEGE OF SURGEONS IN IRELAND No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-09-23

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 Expected Outcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

ROYAL COLLEGE OF SURGEONS IN...

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 23 meses Fecha Inicio: 2024-09-23
Fecha Fin: 2026-09-22

Líder del proyecto

ROYAL COLLEGE OF SURGEONS IN IRELAND No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Epilepsy is the most common chronic brain disease, affecting ~70 million people worldwide. Accurately diagnosing epilepsy remains a major clinical challenge due to the lack of non-invasive molecular diagnostic tools. Purinergic signalling via extracellularly released adenosine triphosphate (ATP) and its downstream purine derivatives is increasingly recognised to contribute to increased hyperexcitability states in the brain, and thus seizures. Hence, these can be potentially identified as novel promising therapeutic targets for the treatment of epilepsy but also as a source of disease-specific biomarkers. However, the diagnostic potential of purinergic signalling for epilepsy remains unclear, and current methods of detection are either unsuitable for point-of-care application or lack disease specificity. Employing a multidisciplinary approach including sensor development, testing in preclinical models of epilepsy, and testing in patients, we will develop a new, user-friendly point-of-care sensor which allows the measurement of specific purines and evaluate the diagnostic potential of blood purine expression changes. Combining my research experience in the development of biosensors with the expertise of my primary (Dr Tobias Engel, RCSI) and secondment (Prof Nicholas Dale, University of Warwick; Prof Norman Delanty, Beaumont Hospital; Prof Felix Rosenow, Frankfurt University) supervisors on purinergic signalling and the development diagnostic devices, ATPsensor will increase our understanding of purinergic signalling and provide new tools to support the diagnosis of epilepsy. The skills acquired during the research project, the excellent training record of the supervisors and host institutions, and the outstanding resources for learning and development available at RCSI and collaborator institutions will give me the tools necessary to become a highly employable neuroscientist.

Conecta tu I+D

Entra hoy

Forgot your password?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores